Physician profile
Samad Khan
NPI 1780944496
$196.38
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.20 · 2020: $57.52 · 2021: $71.57 · 2022: $55.09.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $43.93 | 2020-2022 | |
| Cardiovascular Systems INC. | $29.96 | 2020 | |
| Abbott Laboratories | $28.71 | 2019-2021 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Allergan, INC. | $20.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.66 | 2021 | |
| Genentech USA, INC. | $17.89 | 2021 | |
| Amgen INC. | $13.49 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.